Skip to main
CODX
CODX logo

Co-Diagnostics (CODX) Stock Forecast & Price Target

Co-Diagnostics (CODX) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Co-Diagnostics Inc. reported a net loss of $9.7 million, equivalent to ($0.32) per share, which was better than the previously estimated loss of $10.6 million. This reflects improved financial performance relative to expectations, indicating effective cost management and operational efficiencies. The company's focus on developing low-cost diagnostic systems and reagents for a range of infectious diseases positions it favorably within the molecular diagnostics market.

Bears say

Co-Diagnostics Inc. reported total revenue of $0.6 million for the period, reflecting a substantial year-over-year decline of 74%, despite exceeding projections of $0.4 million. The company faced significant challenges, including a net loss of $9.7 million in 3Q24 and risks tied to lower product uptake, regulatory compliance issues, and the potential inability to develop additional infectious disease-related products. Such financial setbacks and operational uncertainties contribute to a negative outlook for the company's stock.

Co-Diagnostics (CODX) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Co-Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Co-Diagnostics (CODX) Forecast

Analysts have given Co-Diagnostics (CODX) a Buy based on their latest research and market trends.

According to 4 analysts, Co-Diagnostics (CODX) has a Buy consensus rating as of Jun 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Co-Diagnostics (CODX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.